Tharimmune (NASDAQ:THAR) Earns Buy Rating from Analysts at Rodman & Renshaw

Research analysts at Rodman & Renshaw started coverage on shares of Tharimmune (NASDAQ:THAR) in a report issued on Friday,Benzinga reports. The firm set a “buy” rating and a $17.00 price target on the stock.

Tharimmune Stock Up 10.8 %

Shares of NASDAQ THAR opened at $2.25 on Friday. The business has a fifty day moving average price of $2.29 and a two-hundred day moving average price of $2.99. Tharimmune has a fifty-two week low of $1.84 and a fifty-two week high of $9.79.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC purchased a new stake in Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune at the end of the most recent quarter. Institutional investors and hedge funds own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).